Lundbeck Seattle Biopharmaceuticals

Lundbeck Seattle Biopharmaceuticals is a pharmaceutical development company based in Bothell, Washington. Formerly known as Alder Biopharmaceuticals, it specializes in therapeutic monoclonal antibodies.

Lundbeck Seattle Biopharmaceuticals

Formerly	Alder Biopharmaceuticals
Company type	Subsidiary
Founded	1 January 2004 2004
Headquarters	Bothell, Washington , U.S.
Parent	Lundbeck
Website	https://www.lundbeck.com/us/about-us/lundbeck-in-the-us

In May 2014, Alder went public.^[1] In early 2018, the company made a public stock offering, aiming to raise US$250 million.^[2] The company identifies, develops, and manufactures antibody therapeutics to alleviate human suffering in cancer, pain, cardiovascular, and autoimmune and inflammatory disease areas.^[3]

As of September 2019, the Alder Biopharmaceuticals shares have increased with 83% in price, following the company's acquisition by the Denmark-based H. Lundbeck, in a deal valued at $1.95 billion.^[4][5] The company subsequently changed its name to Lundbeck Seattle Biopharmaceuticals after the acquisition.^[6]